Phase II trial of Bisantrene for metastatic melanoma: an Illinois cancer council study.
Sixteen patients with metastatic melanoma entered this phase II study of the efficacy of monthly cycles of Bisantrene. Toxicity was characterized by leukopenia, resulting in the hospitalization of one patient for a febrile incident, and superficial phlebitis. The results were similar to those of previous studies, in that among the 13 patients evaluable for response (six previously untreated with chemotherapy) there were no responses.
Stiff
P J
PJ
Department of Medicine, Southern Illinois University School of Medicine, Springfield.
Sweet
D
D
Kilton
L J
LJ
Johnson
C M
CM
Muntean
B
B
Blough
R R
RR
D000328:Adult; D000368:Aged; D000873:Anthracenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007087:Illinois; D007262:Infusions, Intravenous; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary*; D008875:Middle Aged; D010689:Phlebitis / Q000139:chemically induced; D015996:Survival Rate
D000873:Anthracenes; D000903:Antibiotics, Antineoplastic; C031404:bisantrene